Form 4: Disc Medicine CMO Receives Significant Equity Grants

Disc Medicine's Chief Medical Officer, William Jacob Savage, was granted 17,000 restricted stock units and options to purchase 25,500 shares of common stock.

Summary

• William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc. (IRON), was granted 17,000 restricted stock units (RSUs) on February 10, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest annually in four 25% installments, commencing on February 15, 2027, contingent on continued service.
• Additionally, Savage was granted options to purchase 25,500 shares of common stock on February 10, 2026, with an exercise price of $74.75 per share.
• These stock options will vest in 48 equal monthly installments, beginning on March 10, 2026, also contingent on continued service.
• Following these transactions, Savage beneficially owns 95,845 shares of common stock and 25,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with shareholder interests and promoting retention. It's not a major catalyst but a foundational element of corporate governance.

Positives

• The grants align the Chief Medical Officer's interests with those of shareholders, incentivizing long-term performance.
• The equity awards serve as a retention mechanism for a key executive.
• The vesting schedules encourage continued service and commitment to the company's future.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedules of the granted equity.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are standard components of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align the interests of executives with long-term shareholder value creation and to incentivize retention in a highly competitive talent market. The specific terms, including vesting schedules and exercise prices, are typically benchmarked against peer companies to ensure competitive compensation.

Comparison to Industry Standards

• The grant of RSUs and stock options to a Chief Medical Officer is a common practice in the biopharmaceutical industry, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to attract and retain top scientific and medical talent.
• The vesting schedule of four years for both RSUs (annual 25% installments) and stock options (48 equal monthly installments) is a standard industry practice, designed to promote long-term commitment and performance.
• The exercise price of $74.75 for the stock options would typically be set at the fair market value of the company's stock on the grant date, which is a standard practice for incentive stock options.

Related Party Transactions

• The equity grants to William Jacob Savage, Chief Medical Officer, constitute related party transactions as they involve compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: The grants align the Chief Medical Officer's interests with long-term shareholder value, but also represent potential future dilution upon vesting and exercise.
• Employees: The grants demonstrate the company's commitment to executive compensation and retention, which can positively influence overall employee morale and talent attraction.
• Management: The grants provide significant long-term incentives and compensation for the Chief Medical Officer, encouraging continued service and performance.

Next Steps

• The RSUs will begin vesting on February 15, 2027, in four annual 25% installments.
• The stock options will begin vesting on March 10, 2026, in 48 equal monthly installments.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation in the form of equity grants. While these grants align management incentives with shareholder interests and aid in retention, they do not present new information that would fundamentally alter the investment thesis for Disc Medicine. The filing itself is not a catalyst for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as investors should rely on broader company fundamentals and market conditions.

Keywords

Disc Medicine, IRON, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, William Jacob Savage, Chief Medical Officer